Joint Clinical Trials Office
Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 16, 2026
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 6, 2026
A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2026
Expanded Access Program (EAP) for Obecabtagene Autoleucel (obe-cel) Out-of-specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2026
Comparing the Efficacy and safety of the EndoZip™ System and Apollo ESG, followed by behavioral modifications, in obese patients who have not achieved weight reduction through non-surgical methods
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 7, 2026
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 7, 2026
ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 12, 2026
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 4, 2026
ASPECT Study (Assessment of SIGNATERA genome PErformance across Cancer Types)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 4, 2026
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 4, 2026